1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-7 of 7 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2013European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al.
2009Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Branford, S.; Vaz de Melo, J.; Hughes, T.
2009Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMuller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
2011Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapyParker, W.; Lawrence, R.; Ho, M.; Irwin, D.; Scott, H.; Hughes, T.; Branford, S.
2012Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileParker, W.; Ho, M.; Scott, H.; Hughes, T.; Branford, S.
2008Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsHiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
2013Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cellsHiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.

Discover